Insilico Medicine

Insilico is a clinical stage end-to-end artificial intelligence (AI)-driven drug discovery company that is connecting biology, chemistry, and clinical trials analysis using next-generation AI systems.

Insilico is dedicated to extending human productive longevity and transforming every step of the drug discovery and drug development process through excellence in biomarker discovery, drug development, digital medicine, and aging research.

Insilico Medicine was founded in 2014 by Alex Zhavoronkov. The company is headquartered in Hong Kong, with R&D and management resources in the USA, Belgium, Russia, UK, Taiwan, and China.

 

Insilico has developed AI platforms that utilize deep generative models, reinforcement learning, transformers, and other modern machine learning techniques to discover novel targets and to design novel molecular structures with desired properties. 

 

Insilico has co-development and software licensing deals with a number of major pharmaceutical companies. The company's flagships PandaOmics™ and Chemistry42™ is used by nine out of the top 20 pharmaceutical companies.

 

Insilico has collaborated with first-in-class biopharmaceutical companies, including Pfizer, Fosun Pharma, Syngenta, EQR, Astellas, Johnson & Johnson, Taisho, and many others, with multiple partners reaching major milestones.

 

Insilico is backed by Warburg Pincus, Qiming Venture Partners, Pavilion Capital, Aramco Ventures' Prosperity7, Deerfield, Eight Roads Ventures, B Capital, CPE, OrbiMed, Lilly Asia Ventures, BHR Partners, Sinovation Ventures, and others. The company closed its Series D2 round on Aug 10, 2022, bringing the total Series D financing to $95M. The new investment also brings Insilico's total funding to $401.3M to date.

 

 

  • Year founded: 2014
  • Funding Info: $401.3M over 6 Rounds (Latest Funding Type: Series D2)
  • Yearly Revenue: NA
  • Employee Size: 51-200
  • Business Valuation: NA
  • City/Town: Hong Kong
  • State: HK
  • Country: Hong Kong
Related businesses